INTRODUCTION
The accuracy of a screening test is usually determined by a comparison between the test results and a reference ("gold") standard that ascertains true disease status. Common measures of test accuracy are the true positive rate (TPR, sensitivity), the probability of a positive test result given that the person has the disease, and the false positive rate (FPR; l-specificity), the probability of a positive test result given that the person does not have the disease.
To compare two alternative dichotomous screening tests, information could be derived from screening each person with both tests. Unbiased estimates of the TPR and FPR are obtained if verification by the reference standard is done on consecutive people to whom the tests have been applied.
In this case the TPR and FPR may be calculated directly for each test and the results compared. In practice, however, it is common to verify only those testing positive on either test [l-5] . In a screening population, the number of diseased people is very small in comparison to the number of nondiseased people. Clinicians are ethically bound to investigate anyone with a positive result. However it is often considered "impractical, time consuming, costly, and probably 
These test characteristics cannot be calculated directly from the on the information available and the disease prevalence in the target population to which the results will be applied. In particular, we deal with the common situation where one test has a higher TPR than the other at the expense of having a higher FPR. This trade-off is represented by the ratio of extra false positives (FPs) detected to extra true positives (TPs) detected and is denoted as the "FP:TP ratio." Figure 1 is a user's guide to the methods of test comparison described below. Clearly the number of extra true positives or extra false positives detected by one test compared with the other is also prevalence dependent.
METHODS
Using a sample of 10,000 with absolute differences in TPR and FPR fixed at 0.2 and 0.1, respectively, the number of extra true positives (false positives) could be 2 (999), 20 (990), or 400 (800) depending on whether the prevalence is 0.001, 0.01, or 0.2.
With our sampling scheme, the absolute differences in TPR and FPR and the prevalence of the sampled population are usually unknown so the impact of the trade-off can only be captured by directly comparing the number of true positives and false positives detected by each test. i.e., (b -c) and (B -C) (using Table 1 ). The possible outcomes are shown in Table 2 The results are given in Table 3 [2].
The authors concluded: "Feca EIA has increased the yield of neoplastic disease; however, the high false positive rate makes the best test in its present form unsuitable for screening." The FP:TP ratio confirms the authors' conclusion that the trade-off between FPs and TPs may be too high to implement the Feca EIA screening test. The confidence interval demonstrates the uncertainty associated with the small numbers.
Test Comparison When There Is a TPRIFPR
Trade-Off:
Target and Sampled Population Have Difierent Prevalences
Sometimes the target population may have a different disease prevalence to the sampled population.
For example, screening tests are often evaluated in high-risk populations, defined for example by age or family history, because the yield of diseased cases is greater.
Methods for estimating the FP:TP ratio when the target population has a different prevalence to the sampled population requires additional information.
The following three possibilities will be addressed here: (i) the TPR and FPR of one test is known; (ii) the relative prevalence between two population groups is known; and (iii) assumptions about the data have been made.
~.ITPRANDFPROFONETESTKNOWN.
IftheTPR ofone test is known, then the TPR of the other test may be calculated using the relative TPR. For example, if we know the TPR of Test1 then from Table 1 Assuming test TPR and FPR are independent of disease prevalence, these results can then be generalized to any population group. The impact of the test comparison for a target population with prevalence pr may be determined as follows:
(i) Assume Table 1 represents the data from the sampled population.
The known TPR and FPR of Test1 may be used to estimate ps, the prevalence of the sampled population. (ii) If Table 1 is reconstructed for the target population with the same sample size used in the sampled population, then in comparison to the sampled population, the expected numbers in the diseased group will be multiplied by pT/pS and the expected cells in the non-diseased group will be multiplied by (1 -pT)/(l -p,). Let the relative prevalence r = pJps. Then the FP:TP ratio will be estimated as: It may be possible to obtain the relative prevalence between two distinct population groups. For example, the relative prevalence of different age groups may be estimated using relative incidence rates from a cancer registry. If the relative prevalence (r) of the target population to the sampled population (i.e., r = P~/ps) is known and if ps(or PT) is known (or estimable), then the estimated FP:TP ratio for the target population is represented by Eq. (3.6). In this case however, ps is unknown. As we are dealing with screening populations, ps is usually very small and hence r( 1 -ps) = r. Also, in practice we are more likely to sample a higher risk rather than a lower risk screening population so r will usually be less than 1 and hence (1 -r ps) = 1. In this case we may write If 'r' is treated like a constant, then a minimum estimate of the 95% confidence interval for the FP:TP ratio in the target population may be estimated by applying Eq. (2.1), using the same argument given in section 3.1. The equation requires estimation of the absolute difference in FPR in the numerator and the absolute difference in TPR in the denominator. The estimation of the difference in FPR requires estimation of D. In a screening population where the prevalence of disease is low, the simplest way to estimate D, and hence the difference in FPR, is to assume that all those testing negative on both tests are non-diseased. . This implies that the two screening tests being compared have perfect sensitivity when used in combination and hence that the tests are negatively correlated in the diseased group. Assuming d = 0 is an implausible assumption as tests often measure the same underlying pathophysiological abnormality and is therefore likely to result in verification bias. (2) Assuming tests are independent in the diseased group: As a negative correlation between two screening tests is unlikely, independence is the least association you would expect. Hence if we can assume the data (a, b, c, and d from Table 1) TPRs will fix the marginals of the diseased group in Table  1 and only the interior cells (a, b, c, and d) will change. To model the dependency between tests results, we used the tetrachoric correlation
[13] as it assumes an underlying continuous distribution, which may be the case for many tests. Each scenario (set by the TPRs and prevalence) covered a range of tetrachoric correlations.
The true negative rates of the two tests were restricted to 0.9,0.95, and 0.99 to model screening populations.
To determine the effects of the assumptions in the diseased group only, the two tests were assumed independent in the non-diseased group. Assumptions (1) and (2) were used to estimate the differences in TPR. The differences in FPR were estimated using D*. The scenarios were repeated for sample prevalences of 0.01 and 0.05 and target population prevalences of 0.1 and 0.005. Estimated FP:TP ratios were calculated using Eq. (3.9). A general pattern of results was found to exist across the scenarios examined. Two typical scenarios are presented in Fig.  2 . As expected, Fig. 2 shows that the assumption of independence is consistently better than the assumption that d = 0, and would be preferable in practice.
Clearly, if investigators know of an association between two screening tests then it would be preferable to assume a chosen conditional correlation value rather than assume conditional independence between tests. Theoretically, it should then be possible to estimate d and D from Table 1 and hence estimate the TPRs and FPRs of the two tests and their differences.
DISCUSSION
In the sampling scheme investigated two dichotomous screening tests are simultaneously applied to a random sample from a screening population and only those with a positive result on either test are investigated with the reference standard. This design is both convenient and practical for investigators. Estimating the screening test TPRs and FPRs directly from the data will result in verification bias. Although the relative TPR and relative FPR provide unbiased measures of the relative accuracy of one test to the other, they do not provide enough information in the case of a trade-off. When one test has a higher TPR at the expense of a higher FPR, we measure the trade-off by the FP:TP ratio and its 95% confidence interval. The acceptability of this ratio depends on the screening test and disease of interest and the consequences of investigating people unnecessarily or missing those who really have the disease. For example, with colorectal cancer, intervention may decrease mortality [14] , but false positives need a colonoscopy, which is unpleasant and carries a risk of colon perforation or bleeding.
The FP:TP ratio from a study can be directly applied to populations of the same prevalence as the one sampled. However, it will not be directly applicable to populations with a different disease prevalence. In this paper we show how to use simple assumptions on additional information to estimate FP:TP ratios in target populations which have different prevalences of disease.
To be able to apply published data to a new population using the techniques described requires that the information is presented as in Table 1 and Table 3 [2] in this paper. Therefore, apart from attention to improving the often poor quality of research on diagnostic accuracy [7, 15, 16] , authors should pay attention to the presentation of their data. In the literature studied on the comparison of screening tests for colorectal cancer [12,17], 14 out of 17 studies simultaneously applied two or more screening tests to all participants in the study. Despite this, only one article [4] reported paired data for both the diseased and non-diseased groups. The paired data was calculable in another article [2] and two more reported paired data for the diseased group only [3, 5] . We suggest that authors present their data in the format of Table 1 to allow readers to perform test comparisons for themselves as well as to apply the results to other populations of different disease prevalence. Ultimately, information given in a standard format as the one suggested would also prove useful for meta-analysis.
We The 95% confidence interval for the FP:TP ratio is found by exponentiating these limits.
